Immunovant, Inc. (IMVT)

Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-464.2	-413.84	-259.34	-210.96	-156.73	-107.43
Depreciation & Amortization	0.42	0.38	0.23	0.19	0.13	0.07
Stock-Based Compensation	56.27	49.49	41.12	32.3	34.24	18.82
Other Adjustments	0.1	0.13	1.13	1.13	1.11	0.65
Change in Receivables	0.51	3.23	-4.58	11.76	-11.63	-0.6
Changes in Accounts Payable	-11.21	10.68	5.78	-17.12	16.25	1.25
Changes in Accrued Expenses	7.47	8.92	1.35	15.57	9.47	4.47
Changes in Income Taxes Payable	-	-0.26	0.02	0.46	-0.09	-0.51
Changes in Other Operating Activities	-12.11	-34.61	0.06	-21.52	1.13	-0.05
Operating Cash Flow	-422.89	-375.87	-214.23	-188.19	-106.11	-83.33
Capital Expenditures	-0.2	-0.76	-0.36	-0.2	-0.25	-0.21
Investing Cash Flow	-0.2	-0.76	-0.36	-0.2	-0.25	-0.21
Long-Term Debt Repaid	-	-	-	-	-	-3.19
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-3.19
Issuance of Common Stock	49.44	454.81	478.44	71.16	200.13	387.54
Net Common Stock Issued (Repurchased)	49.44	454.81	478.44	71.16	200.13	387.54
Other Financing Activities	-	-0.32	-6.01	-0.27	-	-1.24
Financing Cash Flow	1,043	454.49	472.43	70.89	200.13	383.11
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.2	0.75	0.99	0.22	-0.09	-
Net Cash Flow	619.84	78.61	258.83	-117.29	93.67	299.58
Free Cash Flow	-423.09	-376.63	-214.59	-188.39	-106.37	-83.54
Free Cash Flow Per Share	-2.44	-2.48	-1.55	-1.53	-0.97	-0.95
Levered Free Cash Flow	-479.82	-429.49	-252.26	-233.58	-130.08	-105.6
Unlevered Free Cash Flow	-506.64	-454.74	-276.25	-240.91	-129.3	-102.74

Updated Feb 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q